Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Delivery
Acusphere Licenses Hydrophobic Drug Delivery System to Cephalon for $10 Million
April 19th, 2008
Acusphere Inc. (NASDAQ: ACUS) announced that it has signed an agreement to license the intellectual property rights to its Hydrophobic Drug Delivery System(TM) (HDDS) for oncology applications, along with the rights to AI-850, its formulation of paclitaxel, to Cephalon, Inc., in exchange for a cash payment of $10 million. "We are very pleased with the terms of this transaction, which establishes a strong value for part of our technology platform that is at an early stage of development," said Sherri C. Oberg, President and CEO of Acusphere. "We are confident that Cephalon is the right partner for one application of this important technology, given its strong focus on...
Source: Law & Health Weekly (2008-04-19)
|
